Natixis Advisors LLC lifted its position in Danaher Co. (NYSE:DHR – Free Report) by 5.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 802,429 shares of the conglomerate’s stock after purchasing an additional 39,029 shares during the quarter. Natixis Advisors LLC owned 0.11% of Danaher worth $223,091,000 at the end of the most recent reporting period.
Other hedge funds have also made changes to their positions in the company. CarsonAllaria Wealth Management Ltd. acquired a new stake in shares of Danaher during the second quarter worth approximately $25,000. nVerses Capital LLC acquired a new stake in Danaher during the 2nd quarter valued at $25,000. MFA Wealth Advisors LLC bought a new position in Danaher in the 2nd quarter valued at $51,000. Financial Connections Group Inc. acquired a new position in Danaher in the second quarter worth $51,000. Finally, Western Pacific Wealth Management LP acquired a new position in Danaher in the first quarter worth $55,000. Institutional investors and hedge funds own 79.05% of the company’s stock.
Insider Buying and Selling at Danaher
In related news, SVP Georgeann Couchara sold 952 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The trade was a 18.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 11.10% of the company’s stock.
Wall Street Analysts Forecast Growth
View Our Latest Stock Analysis on DHR
Danaher Trading Down 3.7 %
NYSE DHR opened at $230.50 on Friday. The stock’s 50-day moving average is $262.20 and its 200-day moving average is $260.38. Danaher Co. has a one year low of $206.30 and a one year high of $281.70. The firm has a market cap of $166.49 billion, a P/E ratio of 43.99, a P/E/G ratio of 4.44 and a beta of 0.85. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.
Danaher (NYSE:DHR – Get Free Report) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.02 EPS. Sell-side analysts anticipate that Danaher Co. will post 7.51 earnings per share for the current fiscal year.
Danaher Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were issued a $0.27 dividend. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.47%. Danaher’s payout ratio is 20.61%.
Danaher Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
See Also
- Five stocks we like better than Danaher
- Top Biotech Stocks: Exploring Innovation Opportunities
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- Stock Sentiment Analysis: How it Works
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- What to Know About Investing in Penny Stocks
- Time to Load Up on Home Builders?
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.